IMMIX BIOPHARMA, INC. Total Liabilities and Equity
IMMIX BIOPHARMA, INC. (IMMX) had Total Liabilities and Equity of $239.11 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-07
- 2026-06-30: Liabilities and Equity $239.11M.
- 2026-03-31: Liabilities and Equity $95.82M.
- 2025-12-31: Liabilities and Equity $104.84M.
- 2025-09-30: Liabilities and Equity $20.08M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $239.11M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $95.82M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $104.84M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $20.08M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $15.64M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $19.89M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $22.95M 10-K/A · filed 2026-03-27 |
| 2024-09-30 | $25.14M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $28.84M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $34.35M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $19.93M 10-K · filed 2025-03-25 |
| 2023-09-30 | $22.47M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $15.57M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $13.21M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $14.91M 10-K · filed 2024-03-29 |
| 2022-09-30 | $17.40M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $19.09M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $20.02M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $18.19M 10-K · filed 2023-03-27 |
| 2020-12-31 | $539.60K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |